Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (101-110 of 236) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical resultsBrian I Rini, Todd Zimmerman, Walter M Stadler, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activityBrian I Rini, Ajit Paintal, Nicholas J Vogelzang, et al.
Biochemical and Biophysical Research Communications|December 19, 2003
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytesReinhard E Marks, Allen W Ho, Fabiola Rivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanomaAmy C Peterson, Susan Swiger, Walter M Stadler, et al.
Blood|June 5, 2007
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional levelReinhard E Marks, Allen W Ho, Christian Robbel, et al.
Immunological Reviews|September 16, 2006
Immune resistance orchestrated by the tumor microenvironmentThomas F Gajewski, Yuru Meng, Christian Blank, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironmentStefani Spranger, Holly K Koblish, Brendan Horton, et al.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
Current Opinion in Immunology|April 13, 2013
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironmentThomas F Gajewski, Seng-Ryong Woo, Yuanyuan Zha, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 17, 2012
Ocular melanoma metastasis to the cervical spineSophia F Shakur, Ippei Takagi, Rimas V Lukas, et al.
Pageof 24

Showing results (101-110 of 236) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical resultsBrian I Rini, Todd Zimmerman, Walter M Stadler, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activityBrian I Rini, Ajit Paintal, Nicholas J Vogelzang, et al.
Biochemical and Biophysical Research Communications|December 19, 2003
Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytesReinhard E Marks, Allen W Ho, Fabiola Rivas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanomaAmy C Peterson, Susan Swiger, Walter M Stadler, et al.
Blood|June 5, 2007
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional levelReinhard E Marks, Allen W Ho, Christian Robbel, et al.
Immunological Reviews|September 16, 2006
Immune resistance orchestrated by the tumor microenvironmentThomas F Gajewski, Yuru Meng, Christian Blank, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironmentStefani Spranger, Holly K Koblish, Brendan Horton, et al.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
Current Opinion in Immunology|April 13, 2013
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironmentThomas F Gajewski, Seng-Ryong Woo, Yuanyuan Zha, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 17, 2012
Ocular melanoma metastasis to the cervical spineSophia F Shakur, Ippei Takagi, Rimas V Lukas, et al.
Pageof 24